Literature DB >> 15730606

Failure of nasogastric omeprazole suspension in pediatric intensive care patients.

Julie A Haizlip1, Ralph A Lugo, Jared J Cash, Donald D Vernon.   

Abstract

OBJECTIVES: To determine the efficacy of nasogastric administration of omeprazole suspension in raising the gastric pH >4 in critically ill pediatric patients and to determine the most appropriate dosing regimen for this indication.
DESIGN: Open-label pharmacodynamic study.
SETTING: Twenty-six bed tertiary-care pediatric intensive care unit. PATIENTS: Mechanically ventilated children aged 1-18 yrs with an additional risk factor for stress ulcer formation.
INTERVENTIONS: Continuous gastric pH monitoring was performed during administration and dose titration of omeprazole suspension to achieve the goal of gastric pH >4 for greater than 75% of the dosing interval.
MEASUREMENTS AND MAIN RESULTS: Data were collected from 18 patients. Subjects were categorized based on the pharmacologic response to nasogastric administration of 1 mg/kg omeprazole suspension (maximum 20 mg) as rapid (n = 9), late (n = 5), and nonresponders (n = 4). Rapid responders required 0.72 mg/kg per day omeprazole suspension to achieve adequate gastric pH elevation for stress ulcer prophylaxis. Late responders required 1.58 mg/kg per day. Nonresponders did not achieve adequate elevation of gastric pH for stress ulcer prophylaxis.
CONCLUSIONS: Nasogastric administration of omeprazole suspension has variable efficacy in critically ill pediatric patients. Half of the studied subjects either required significant dose titrations to achieve gastric acid suppression or did not respond to nasogastric administration of omeprazole suspension.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15730606     DOI: 10.1097/01.PCC.0000154953.12594.9E

Source DB:  PubMed          Journal:  Pediatr Crit Care Med        ISSN: 1529-7535            Impact factor:   3.624


  5 in total

1.  'Poppy seeds' in stomach aspirates: is oral omeprazole extemporaneous dispersion bioavailable?

Authors:  Catherine Tuleu; Sara Arenas-Lopez; Chris Robinson; David McCarthy; Richard I J Paget; Shane Tibby; Kevin M G Taylor
Journal:  Eur J Pediatr       Date:  2007-07-20       Impact factor: 3.183

2.  Administration of proton pump inhibitors in patients requiring enteral nutrition.

Authors:  Terri M Wensel
Journal:  P T       Date:  2009-03

3.  (Es)omeprazole and Discoloration of Regurgitated Gastric Contents in Infants: Worrying for Care-Takers and a Sign of a Reduced Bioavailability.

Authors:  Florence van Hunsel; Loek de Jong; Tjalling de Vries
Journal:  J Pediatr Pharmacol Ther       Date:  2016 May-Jun

Review 4.  Pharmacokinetics of proton pump inhibitors in children.

Authors:  Catherine Litalien; Yves Théorêt; Christophe Faure
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

5.  Acid reducing agents to neonates - lack of evidence and guidelines.

Authors:  Stina Paulsson; Staffan Eksborg; Åsa Andersson; Per Nydert; Lena Grahnquist
Journal:  J Drug Assess       Date:  2012-01-09
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.